Antonio Cavazos

794 total citations
25 papers, 264 citations indexed

About

Antonio Cavazos is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Antonio Cavazos has authored 25 papers receiving a total of 264 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Hematology, 16 papers in Molecular Biology and 6 papers in Oncology. Recurrent topics in Antonio Cavazos's work include Acute Myeloid Leukemia Research (15 papers), Protein Degradation and Inhibitors (8 papers) and Acute Lymphoblastic Leukemia research (5 papers). Antonio Cavazos is often cited by papers focused on Acute Myeloid Leukemia Research (15 papers), Protein Degradation and Inhibitors (8 papers) and Acute Lymphoblastic Leukemia research (5 papers). Antonio Cavazos collaborates with scholars based in United States, China and Taiwan. Antonio Cavazos's co-authors include Marina Konopleva, Vinitha M. Kuruvilla, Qi Zhang, Monique Dail, Marina Konopleva, Deepak Sampath, RosaAnna DeFilippis, Vidhi Mody, Neil P. Shah and Raghuveer Singh Mali and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Antonio Cavazos

25 papers receiving 262 citations

Peers

Antonio Cavazos
Ahmad Antar Lebanon
Jean‐Valère Malfuson France
Mélanie Pannetier France
Álex Bataller United States
Niklas Landberg Sweden
Edwin Kingsley United States
M Martín-Ayuso Spain
Haytham Khoury Canada
Lars Fransecky Germany
Corina Schneidawind Germany
Ahmad Antar Lebanon
Antonio Cavazos
Citations per year, relative to Antonio Cavazos Antonio Cavazos (= 1×) peers Ahmad Antar

Countries citing papers authored by Antonio Cavazos

Since Specialization
Citations

This map shows the geographic impact of Antonio Cavazos's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Antonio Cavazos with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Antonio Cavazos more than expected).

Fields of papers citing papers by Antonio Cavazos

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Antonio Cavazos. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Antonio Cavazos. The network helps show where Antonio Cavazos may publish in the future.

Co-authorship network of co-authors of Antonio Cavazos

This figure shows the co-authorship network connecting the top 25 collaborators of Antonio Cavazos. A scholar is included among the top collaborators of Antonio Cavazos based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Antonio Cavazos. Antonio Cavazos is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Koller, Paul, Natalia Baran, Karine G. Harutyunyan, et al.. (2023). PD-1 blockade in combination with dasatinib potentiates induction of anti-acute lymphocytic leukemia immunity. Journal for ImmunoTherapy of Cancer. 11(10). e006619–e006619. 4 indexed citations
2.
Zeng, Zhihong, Abhishek Maiti, Shelley M. Herbrich, et al.. (2022). Triple combination targeting methyltransferase, BCL‐2, and PD‐1 facilitates antileukemia responses in acute myeloid leukemia. Cancer. 129(4). 531–540. 7 indexed citations
3.
Mali, Raghuveer Singh, Qi Zhang, RosaAnna DeFilippis, et al.. (2020). Venetoclax combines synergistically with FLT3 inhibition to effectively target leukemic cells in FLT3-ITD+ acute myeloid leukemia models. Haematologica. 106(4). 1034–1046. 97 indexed citations
4.
Harutyunyan, Karine G., Natalia Baran, Saradhi Mallampati, et al.. (2020). Inhibition of Oxidative Phosphorylation Reverses Bone Marrow Hypoxia Visualized in Imageable Syngeneic B-ALL Mouse Model. Frontiers in Oncology. 10. 991–991. 12 indexed citations
5.
6.
Zeng, Zhihong, Natalia Baran, Sergej Konoplev, et al.. (2019). Targeting DHODH with AG-636 Induces Apoptosis and Differentiation and Inhibits Mitochondrial Function in AML, Translating into Anti-Tumor Efficacy in Vitro and in Vivo. Blood. 134(Supplement_1). 3911–3911. 2 indexed citations
7.
Han, Lina, Antonio Cavazos, Natalia Baran, et al.. (2019). Mitochondrial Oxphos As Survival Mechanism of Minimal Residual AML Cells after Induction Chemotherapy : Survival Benefit By Complex I Inhibition with Iacs-010759. Blood. 134(Supplement_1). 5161–5161. 15 indexed citations
8.
Zhang, Qi, Alessia Lodi, Shannon Sweeney, et al.. (2019). Inhibiting Mitochondria Function By Bcl-2 Inhibitor Venetoclax and Complex I Inhibitor Iacs-010759 Eliminate Leukemia Cells in Pre-Clinical AML Models. Blood. 134(Supplement_1). 3927–3927. 1 indexed citations
9.
Cai, Tianyu, Vinitha M. Kuruvilla, Xiaoyu Lin, et al.. (2019). Selective Targeting BET Family Bdii Bromodomain with Abbv-744 and BCL-2 with Venetoclax (ABT-199) Is Synergistic in Primary Acute Myeloid Leukemia Models. Blood. 134(Supplement_1). 1369–1369. 2 indexed citations
10.
11.
Boddu, Prajwal, Gautam Borthakur, Kiran Naqvi, et al.. (2018). Initial report of a phase I study of LY2510924 with idarubicin and cytarabine (IA) in relapsed/refractory (R/R) AML.. Journal of Clinical Oncology. 36(15_suppl). 7026–7026. 1 indexed citations
12.
Boddu, Prajwal, Gautam Borthakur, Mythili Koneru, et al.. (2018). Initial Report of a Phase I Study of LY2510924, Idarubicin, and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia. Frontiers in Oncology. 8. 369–369. 30 indexed citations
13.
Cai, Tianyu, Vinitha M. Kuruvilla, Tamar Uziel, et al.. (2018). Targeting the Second Bromodomain (BDII) of BET Family with Abbv-744 Results in Robust Anti-Leukemia Activity in AML Models with Excellent In Vivo Tolerability. Blood. 132(Supplement 1). 1439–1439. 1 indexed citations
14.
DiNardo, Courtney D., Maher Albitar, Tapan M. Kadia, et al.. (2018). Venetoclax in Combination with FLAG-IDA Chemotherapy (FLAG-V-I) for Fit, Relapsed/Refractory AML Patients: Interim Results of a Phase 1b/2 Dose Escalation and Expansion Study. Blood. 132(Supplement 1). 4048–4048. 16 indexed citations
15.
Baran, Natalia, Shannon Sweeney, Alessia Lodi, et al.. (2017). Inhibition of Oxphos with Iacs-010759 Depletes AML Leukemia Initiating Cells (LIC) in Vitro and Improves Survival in Pre-Clinical AML Models. Blood. 130. 1350–1350. 1 indexed citations
16.
Cavazos, Antonio, Natalia Baran, Qi Zhang, et al.. (2017). Targeting Residual Chemotherapy-Resistant Acute Myeloid Leukemia Cells By a Novel Oxphos Inhibitor IACS010759. Blood. 130. 2623–2623. 2 indexed citations
17.
18.
Cavazos, Antonio, Helen Ma, Juliana M. Benito, et al.. (2016). Pre-Clinical Activity of Novel Hypoxia-Activated FLT3 Inhibitors in FLT3-Mutated AML. Blood. 128(22). 5210–5210. 1 indexed citations
19.
Cai, Tianyu, Román Galetto, Agnès Gouble, et al.. (2016). Pre-Clinical Studies of Anti-CD123 CAR-T Cells for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). Blood. 128(22). 4039–4039. 20 indexed citations
20.
Cavazos, Antonio, et al.. (1976). Familial thymic aplasia with intrauterine growth retardation and fetal death: a new syndrome or a variant of DiGeorge syndrome.. PubMed. 12(6). 123–5. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ahmad Antar Breakdown of academic impact, for papers by Jean‐Valère Malfuson Breakdown of academic impact, for papers by Mélanie Pannetier Breakdown of academic impact, for papers by Álex Bataller Breakdown of academic impact, for papers by Niklas Landberg Breakdown of academic impact, for papers by Edwin Kingsley Breakdown of academic impact, for papers by M Martín-Ayuso Breakdown of academic impact, for papers by Haytham Khoury Breakdown of academic impact, for papers by Lars Fransecky Breakdown of academic impact, for papers by Corina Schneidawind
Rankless by CCL
2026